Details
Stereochemistry | ABSOLUTE |
Molecular Formula | 2C25H43N13O10.3H2O4S |
Molecular Weight | 1665.615 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 14 / 14 |
E/Z Centers | 2 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.[H][C@@]1(CCNC(=N)N1)[C@]2([H])NC(=O)\C(NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CNC2=O)NC(=O)C[C@@H](N)[C@H](O)CCN)=C\NC(N)=O.[H][C@@]3(CCNC(=N)N3)[C@]4([H])NC(=O)\C(NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CNC4=O)NC(=O)C[C@@H](N)[C@H](O)CCN)=C\NC(N)=O
InChI
InChIKey=DZKQVWCTFCSEKF-QOEBQMAPSA-N
InChI=1S/2C25H43N13O10.3H2O4S/c2*26-3-1-16(41)10(27)5-17(42)33-12-6-31-23(47)18(11-2-4-30-24(28)37-11)38-20(44)13(7-32-25(29)48)34-21(45)14(8-39)36-22(46)15(9-40)35-19(12)43;3*1-5(2,3)4/h2*7,10-12,14-16,18,39-41H,1-6,8-9,26-27H2,(H,31,47)(H,33,42)(H,34,45)(H,35,43)(H,36,46)(H,38,44)(H3,28,30,37)(H3,29,32,48);3*(H2,1,2,3,4)/b2*13-7-;;;/t2*10-,11-,12+,14+,15+,16-,18+;;;/m11.../s1
Molecular Formula | C25H43N13O10 |
Molecular Weight | 685.69 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 2 |
Optical Activity | UNSPECIFIED |
Molecular Formula | H2O4S |
Molecular Weight | 98.078 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/4308717Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/2539957 | https://www.ncbi.nlm.nih.gov/pubmed/17571483
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4308717
Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/2539957 | https://www.ncbi.nlm.nih.gov/pubmed/17571483
Enviomycin, antimicrobial drug, was isolated in Japan from fermentation broth of Syteptomyces griseoverticillatus var tuberacticus. This drug, a water-soluble, basic peptide, is effective against tubercle bacilli as well as some gram-positive and gram-negative bacteria. It is related to viomycin and cepreomycin in some of its physicochemical properties. It is used for the treatment of Mycobacterium avium caused lung diseases.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0000372 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7509881 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
[A case of pulmonary Mycobacterium fortuitum infection successfully treated with Kampo treatments]. | 2006 Aug |
|
[Case of pulmonary multi-drug resistant tuberculosis with left destroyed lung, treated with pneumonectomy]. | 2007 Jul |
|
[Case of multi-drug resistant pulmonary tuberculosis with bilateral cavitary lesions successfully treated by surgical treatment]. | 2007 Nov |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2539957
1 g/day three times weekly
Route of Administration:
Unknown
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1406364
Enviomycin is bactericidal against Mycobacterium avium strain 13887 with MIC=1.6 ug/ml.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 05:22:52 GMT 2023
by
admin
on
Sat Dec 16 05:22:52 GMT 2023
|
Record UNII |
67846BXW65
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL2146142
Created by
admin on Sat Dec 16 05:22:52 GMT 2023 , Edited by admin on Sat Dec 16 05:22:52 GMT 2023
|
PRIMARY | |||
|
DTXSID10202038
Created by
admin on Sat Dec 16 05:22:52 GMT 2023 , Edited by admin on Sat Dec 16 05:22:52 GMT 2023
|
PRIMARY | |||
|
m4924
Created by
admin on Sat Dec 16 05:22:52 GMT 2023 , Edited by admin on Sat Dec 16 05:22:52 GMT 2023
|
PRIMARY | Merck Index | ||
|
SUB21807
Created by
admin on Sat Dec 16 05:22:52 GMT 2023 , Edited by admin on Sat Dec 16 05:22:52 GMT 2023
|
PRIMARY | |||
|
100000086037
Created by
admin on Sat Dec 16 05:22:52 GMT 2023 , Edited by admin on Sat Dec 16 05:22:52 GMT 2023
|
PRIMARY | |||
|
71587175
Created by
admin on Sat Dec 16 05:22:52 GMT 2023 , Edited by admin on Sat Dec 16 05:22:52 GMT 2023
|
PRIMARY | |||
|
DBSALT001086
Created by
admin on Sat Dec 16 05:22:52 GMT 2023 , Edited by admin on Sat Dec 16 05:22:52 GMT 2023
|
PRIMARY | |||
|
67846BXW65
Created by
admin on Sat Dec 16 05:22:52 GMT 2023 , Edited by admin on Sat Dec 16 05:22:52 GMT 2023
|
PRIMARY | |||
|
53760-33-1
Created by
admin on Sat Dec 16 05:22:52 GMT 2023 , Edited by admin on Sat Dec 16 05:22:52 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |